Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results matching your filters

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)Recruiting
NCT06824467Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
United States, Argentina, Australia, Austria, Belgium +24 more
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruiting
NCT07555938Phase 3Updated Aug 14, 2026
Sponsor: Hoffmann-La Roche
Multiple Myeloma
United States, Canada, Germany, Greece, Israel +6 more
Randomized Study in Children and Adolescents With Migraine: Acute TreatmentRecruiting
NCT04649242Phase 3Updated Aug 14, 2026
Sponsor: Pfizer
Pediatric Migraine
United States, Canada, China, Japan, Mexico +4 more
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesRecruiting
NCT07351045Phase 3Updated Aug 14, 2026
Sponsor: Hoffmann-La Roche
Obesity or Overweight
United States, Argentina, Australia, Belgium, Brazil +15 more
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.Recruiting
NCT06713837Phase 3Updated Aug 14, 2026
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Acute Myeloid Leukemia · Relapse/Recurrence
Czechia, Germany, Italy, Lithuania, Portugal +2 more
Surgical Treatment for Gingival Recessions After Orthodontic TreatmentRecruiting
NCT07763808Phase 2, Phase 3Updated Aug 13, 2026
Sponsor: Aziz Aliyev Azerbaijan State Advanced Training Institute for Doctors
Gingival Recessions, Generalized
Azerbaijan
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)Recruiting
NCT07500090Phase 3Updated Aug 13, 2026
Sponsor: Harmony Biosciences Management, Inc.
Idiopathic Hypersomnia
United States
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruiting
NCT06970639Phase 3Updated Aug 13, 2026
Sponsor: Allist Pharmaceuticals, Inc.
NSCLC Patients With Brain Metastasis
China
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, RespectivelyRecruiting
NCT07424404Phase 3Updated Aug 13, 2026
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia · Autism-Related Irritability
United States, Argentina, Australia, Canada, France +6 more
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Recruiting
NCT07234032Phase 3Updated Aug 13, 2026
Sponsor: Insmed Incorporated
Pulmonary Hypertension · Interstitial Lung Disease
United States, Japan, South Korea, Spain, Taiwan
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With AsthmaRecruiting
NCT06307665Phase 3Updated Aug 13, 2026
Sponsor: AstraZeneca
Asthma
United States, China, Mexico, South Africa
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)Recruiting
NCT07288567Phase 3Updated Aug 13, 2026
Sponsor: Bristol-Myers Squibb
Schizophrenia
United States, Colombia, Japan, Romania
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0Recruiting
NCT05476939Phase 3Updated Aug 13, 2026
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Diffuse Intrinsic Pontine Glioma · Diffuse Midline Glioma, H3 K27M-Mutant · Diffuse Midline Glioma, H3K27-altered
Denmark, Finland, France, Norway, Spain +1 more
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationRecruiting
NCT06416410Phase 3Updated Aug 13, 2026
Sponsor: Allist Pharmaceuticals, Inc.
Advanced Non-squamous Non-small-cell Lung Cancer · Metastatic Non-squamous Non Small Cell Lung Cancer
China
InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpressionRecruiting
NCT06781697Phase 3Updated Aug 13, 2026
Sponsor: Sunnybrook Health Sciences Centre
Treatment Resistant Depression
Canada
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q MutationRecruiting
NCT06956001Phase 3Updated Aug 13, 2026
Sponsor: Allist Pharmaceuticals, Inc.
EGFR · NSCLC (Advanced Non-small Cell Lung Cancer)
China
Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerRecruiting
NCT07251582Phase 3Updated Aug 13, 2026
Sponsor: Hunan Province Tumor Hospital
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
China
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyRecruiting
NCT04853342Phase 3Updated Aug 13, 2026
Sponsor: Allist Pharmaceuticals, Inc.
Non-small Cell Lung Carcinoma
China
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）Recruiting
NCT07010419Phase 3Updated Aug 13, 2026
Sponsor: Allist Pharmaceuticals, Inc.
NSCLC · Adjuvant Treatment
China
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)Recruiting
NCT06136650Phase 3Updated Aug 13, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer (mCRPC) · Prostatic Neoplasms
United States, Australia, Brazil, Canada, Chile +34 more
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerRecruiting
NCT06712316Phase 2, Phase 3Updated Aug 13, 2026
Sponsor: BioNTech SE
Non-small Cell Lung Cancer
United States, Australia, Belgium, Brazil, Bulgaria +15 more
Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis BullosaRecruiting
NCT07482787Phase 3Updated Aug 13, 2026
Sponsor: Paradigm Therapeutics
Epidermolysis Bullosa (EB)
United States
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia AreataRecruiting
NCT06873945Phase 3Updated Aug 13, 2026
Sponsor: Pfizer
Alopecia Areata
United States, Canada, China, Czechia, Japan +6 more
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With HyperkalaemiaRecruiting
NCT03813407Phase 3Updated Aug 13, 2026
Sponsor: AstraZeneca
Hyperkalaemia
United States, Brazil, Canada, China, Germany +8 more
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)Recruiting
NCT06708299Phase 3Updated Aug 13, 2026
Sponsor: Cardiol Therapeutics Inc.
Recurrent Pericarditis
United States, Canada, Greece, Italy

Previous page Next page